Last updated: August 28, 2026
Nilutamide is an off-patent, orally administered nonsteroidal antiandrogen with a low-dose immediate-release tablet as its established dosage form. The commercial opportunity is primarily in low-cost generic supply, differentiated excipient systems, alternative oral presentations, and regional markets where access to androgen-deprivation therapy remains limited. The main technical constraints are poor aqueous solubility, long elimination half-life, hepatotoxicity, pulmonary toxicity, and the need to demonstrate pharmaceutical equivalence to the reference product.
What is nilutamide and how is it currently formulated?
Nilutamide is a nonsteroidal androgen-receptor antagonist approved for use with surgical castration in the treatment of metastatic prostate cancer. The U.S. reference product is Nilandron, supplied as a 150 mg tablet. The approved regimen begins with 300 mg once daily for 30 days, followed by 150 mg once daily [1].
| Attribute |
Nilutamide |
| Active ingredient |
Nilutamide |
| Drug class |
Nonsteroidal antiandrogen |
| Molecular formula |
C12H10F3N3O4 |
| Molecular weight |
317.22 g/mol |
| Reference product |
Nilandron |
| Dosage form |
Immediate-release tablet |
| Strength |
150 mg |
| FDA approval |
1996 |
| Primary indication |
Metastatic prostate cancer with surgical castration |
| Administration |
Oral, once daily after loading period |
| Key safety constraints |
Hepatotoxicity, interstitial pneumonitis, visual adaptation impairment, alcohol intolerance |
The Nilandron tablet uses conventional excipients, including lactose, corn starch, povidone, sodium lauryl sulfate, magnesium stearate, and coloring or coating agents, according to product labeling [1]. The formulation is compatible with a standard wet-granulation or dry-granulation generic manufacturing platform.
What excipient properties matter most for nilutamide?
Nilutamide development should prioritize dissolution performance, content uniformity, chemical stability, and reproducible absorption rather than complex controlled-release technology.
Solubility and dissolution
Nilutamide has limited aqueous solubility. The drug contains a hydrophobic aromatic structure and a trifluoromethyl group, creating a formulation risk typical of poorly soluble small molecules. Particle-size reduction, surfactant-assisted wetting, improved granule porosity, and solid-state control are the most practical approaches.
Relevant excipient tools include:
- Sodium lauryl sulfate or another low-level surfactant to improve wetting.
- Poloxamers or polysorbates where compatible with tablet stability.
- Crospovidone, croscarmellose sodium, or sodium starch glycolate to accelerate tablet disintegration.
- Copovidone or povidone as a binder.
- Lactose, microcrystalline cellulose, mannitol, or dibasic calcium phosphate as fillers.
- Colloidal silicon dioxide to improve powder flow.
- Magnesium stearate at controlled concentrations to limit hydrophobic over-lubrication.
The formulation should be optimized against discriminatory dissolution methods rather than simply matching disintegration time. Excessive lubricant, high compression force, or excessive hydrophobic filler may delay release and create bioequivalence risk.
Solid-state and particle-size control
A generic developer should characterize particle-size distribution, polymorphic form, crystallinity, and moisture sensitivity. Milling can improve dissolution but may increase electrostatic charging, agglomeration, and process variability.
A practical development sequence is:
- Establish the reference product's dissolution profile across multiple pH conditions.
- Screen micronized and unmilled nilutamide.
- Compare direct compression, dry granulation, and wet granulation.
- Add a disintegrant-surfactant combination.
- Confirm chemical and physical stability under ICH conditions.
- Select the simplest formulation that matches the reference profile.
Amorphous solid dispersions may improve dissolution but introduce physical stability and scale-up risks. They are more attractive for a differentiated oral suspension or low-volume formulation than for a conventional 150 mg generic tablet.
What formulations are protected by nilutamide patents?
The principal commercial product is an immediate-release tablet, and nilutamide is an old active pharmaceutical ingredient. Its original compound and product protection have expired or are commercially obsolete in the United States.
The current opportunity does not depend on blocking patents covering the molecule. It depends on manufacturing cost, regulatory execution, supply reliability, and differentiated formulation claims.
| Protection category |
Commercial assessment |
| Original compound patent |
Expired or no longer commercially relevant |
| Original tablet formulation |
No meaningful current barrier expected |
| U.S. Orange Book-listed patents |
No significant active protection is generally associated with the legacy product |
| New formulation patents |
Available for novel delivery systems if non-obvious and clinically relevant |
| Method-of-use patents |
Limited value because the core prostate-cancer use is established |
| Manufacturing patents |
Possible for particle engineering, solid dispersions, or continuous processing |
| Regulatory exclusivity |
Expired for the legacy product |
| Biosimilar exclusivity |
Not applicable to this small-molecule drug |
The Orange Book should be reviewed at the time of ANDA submission because listings and reference-product designations can change [2]. A new product that relies on a novel formulation may pursue a separate 505(b)(2) strategy, but a conventional tablet would normally favor an ANDA pathway if an appropriate reference product is available.
When did nilutamide lose market exclusivity?
Nilutamide lost meaningful U.S. market exclusivity years ago. Nilandron was approved by the FDA in 1996, placing the product well beyond its original five-year new-chemical-entity exclusivity period and the term of ordinary compound patent protection [1, 3].
Nilutamide exclusivity timeline
| Milestone |
Date or status |
| FDA approval of Nilandron |
1996 |
| New chemical entity exclusivity |
Expired |
| Original compound patent term |
Expired |
| Pediatric exclusivity |
No current commercial relevance |
| Orphan-drug exclusivity |
Not the principal protection for Nilandron |
| Current regulatory position |
Legacy small-molecule product |
| Generic opportunity |
ANDA or, for differentiated products, 505(b)(2) |
The practical result is a low intellectual-property barrier. Any commercial launch must still address reference-product availability, bioequivalence, labeling, pharmacovigilance, and supply-chain economics.
What is the FDA regulatory status of nilutamide?
Nilutamide remains an FDA-approved active ingredient for use in metastatic prostate cancer with surgical castration. Its label carries important safety warnings, including potentially serious hepatic injury and interstitial pneumonitis [1].
The safety profile affects excipient strategy in several ways:
- Avoid excipients with meaningful hepatotoxicity signals.
- Limit unnecessary colorants and preservatives in chronic therapy.
- Maintain batch-to-batch dissolution consistency because exposure can be affected by formulation performance.
- Avoid formulation changes that materially increase exposure without clinical justification.
- Preserve clear labeling regarding alcohol intolerance and visual adaptation effects.
Nilutamide does not have a biosimilar pathway. It is a chemically synthesized small molecule, so competition would arise through ANDAs, 505(b)(2) applications, national generic pathways, or non-U.S. equivalents.
What generic entry risks exist for nilutamide?
The principal risk is market size, not patent litigation. Nilutamide has been commercially disadvantaged by the broader adoption of newer androgen-receptor pathway inhibitors and other prostate-cancer therapies.
Generic launch scenarios
| Scenario |
Product concept |
Commercial outlook |
| Low-cost standard tablet |
150 mg immediate-release tablet |
Most feasible regulatory route |
| Lactose-free tablet |
Microcrystalline cellulose or mannitol platform |
Useful for selected markets and contract customers |
| Orally disintegrating tablet |
Mannitol, crospovidone, taste-masking system |
Niche opportunity; requires strong bioequivalence justification |
| Oral suspension |
Wetting agent, suspending polymer, preservative system |
Useful for swallowing difficulties; higher stability burden |
| Modified-release tablet |
Matrix or coated-particle system |
Limited value because once-daily dosing already exists |
| Fixed-dose combination |
Nilutamide with another oncology agent |
High clinical and regulatory complexity |
| Regional branded generic |
Differentiated packaging and supply reliability |
Potentially viable in underpenetrated markets |
A standard generic tablet offers the clearest route. The challenge is that a small patient population may not support multiple manufacturers unless the product is manufactured through an efficient platform process or sold in markets with limited competition.
What excipient strategy is best for a generic nilutamide tablet?
The preferred approach is a robust immediate-release formulation that matches the reference product without relying on novel excipient technology.
Recommended core platform
A practical formulation could use:
- Nilutamide API with controlled particle size.
- Lactose monohydrate or microcrystalline cellulose as the main diluent.
- Povidone or copovidone as binder.
- Croscarmellose sodium or crospovidone as superdisintegrant.
- A low concentration of sodium lauryl sulfate or comparable wetting agent.
- Colloidal silicon dioxide for flow.
- Magnesium stearate for lubrication.
- A conventional protective film coat.
A lactose-free version could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed excipient. The substitution must be evaluated for tablet hardness, dissolution, friability, and bioequivalence.
Excipient opportunities
The most commercially defensible excipient claims would relate to:
- Improved dissolution at physiologically relevant pH.
- Reduced tablet weight.
- Improved mechanical strength.
- Lactose-free or low-allergen positioning.
- Better stability in humid climates.
- Reduced manufacturing variability.
- Compatibility with automated high-speed compression.
A formulation patent would require more than replacing lactose with microcrystalline cellulose. Patentable value would be stronger where a specific excipient ratio, particle-size distribution, processing method, or solid-state form produces a demonstrated technical effect.
What formulation patents could create new commercial value?
A differentiated nilutamide product could pursue intellectual property in four areas.
1. Enhanced-dissolution formulations
Amorphous solid dispersions, spray-dried dispersions, co-crystals, nanosized API, or surfactant-containing granules could improve dissolution. The commercial case depends on whether the improvement translates into more consistent exposure or permits a clinically useful dosage reduction.
2. Orally disintegrating tablets
An ODT could target elderly patients and patients with dysphagia. Mannitol, crospovidone, low-substitution hydroxypropyl cellulose, and taste-masking coatings are plausible components. Nilutamide's taste and dose size must be assessed because a 150 mg tablet is materially more difficult to formulate as an elegant ODT than a low-dose molecule.
3. Oral liquid formulations
A suspension could address swallowing limitations and institutional-care use. Key challenges include sedimentation, redispersibility, chemical stability, preservative compatibility, and dose uniformity. A small-volume suspension with a controlled particle-size distribution would be more commercially attractive than a high-volume product.
4. Moisture-resistant manufacturing systems
A film coat, desiccant-enabled packaging, or moisture-tolerant granulation process could support distribution in tropical markets. These claims are more likely to support manufacturing or packaging differentiation than premium pricing in the United States.
What patent litigation affects nilutamide?
Nilutamide is unlikely to generate major current Paragraph IV litigation because the legacy product's core exclusivity has expired and the market is limited. A conventional ANDA applicant would typically assess:
- Active Orange Book patents, if any.
- Listed exclusivity.
- Reference-product availability.
- Patent certifications under the Hatch-Waxman framework.
- Any later-issued formulation or use patents.
- State and international patent rights for the intended launch markets.
The more likely legal risk would arise from a new formulation patent owned by a later entrant, not from the original Nilandron product. A 505(b)(2) product with a new dosage form could face patent claims directed to formulation composition, treatment method, or pharmacokinetic performance.
Which companies are challenging or competing with nilutamide?
Nilutamide competes clinically with flutamide, bicalutamide, enzalutamide, apalutamide, darolutamide, abiraterone acetate, and gonadotropin-releasing hormone therapies. The newer agents generally have stronger contemporary commercial positioning.
| Product |
Class |
Commercial comparison with nilutamide |
| Nilutamide |
Nonsteroidal antiandrogen |
Low-cost legacy product; narrow modern use |
| Flutamide |
Nonsteroidal antiandrogen |
Older alternative with liver-toxicity concerns |
| Bicalutamide |
Nonsteroidal antiandrogen |
More established legacy competitor |
| Enzalutamide |
Androgen-receptor inhibitor |
Stronger modern prostate-cancer positioning |
| Apalutamide |
Androgen-receptor inhibitor |
Used in earlier disease settings |
| Darolutamide |
Androgen-receptor inhibitor |
Differentiated safety and combination positioning |
| Abiraterone acetate |
Androgen-synthesis inhibitor |
Major established alternative |
Nilutamide's commercial position depends on price and availability rather than clinical novelty. A generic manufacturer should avoid assuming that approval will create substantial share in markets dominated by newer therapies.
What licensing deals could support nilutamide commercialization?
Licensing opportunities are more likely to involve manufacturing and regional commercialization than ownership of core nilutamide intellectual property.
Potential deal structures include:
- API supply and technology-transfer agreements.
- Contract manufacturing for 150 mg tablets.
- Regional licensing of a lactose-free or ODT formulation.
- Co-development of an oral suspension for institutional markets.
- Portfolio licensing with other generic oncology products.
- Exclusive distribution in countries where Nilandron or generic nilutamide access is limited.
A formulation license has the strongest negotiating value when it includes validated stability data, scale-up history, regulatory documentation, and a clear pathway to approval. A simple excipient substitution is unlikely to justify a large upfront payment.
How strong is the nilutamide patent estate?
The core patent estate is weak from a current commercial perspective because the drug was approved in 1996 and has no biologic exclusivity or active-molecule protection of practical importance. The remaining value is potentially available through new formulation, manufacturing, packaging, or regional rights.
| Estate component |
Strength |
| Core molecule |
Low |
| Original indication |
Low |
| Immediate-release tablet |
Low |
| Novel dissolution system |
Moderate if supported by data |
| ODT or oral suspension |
Moderate, subject to claim quality |
| Manufacturing process |
Moderate for difficult-to-reproduce process controls |
| Packaging and moisture protection |
Low to moderate |
| Geographic rights |
Variable by country |
| Trade secrets |
Potentially meaningful for process know-how |
Key Takeaways
- Nilutamide is an off-patent, FDA-approved small-molecule antiandrogen supplied primarily as a 150 mg immediate-release tablet.
- The lowest-risk commercial strategy is a conventional generic tablet using controlled particle size, a superdisintegrant, a wetting agent, and standard tablet excipients.
- The most credible formulation opportunities are lactose-free tablets, orally disintegrating tablets, oral suspensions, and enhanced-dissolution systems.
- The commercial market is constrained by competition from newer prostate-cancer therapies.
- Patent risk is low for the legacy molecule and high only if a later entrant obtains enforceable formulation or manufacturing claims.
- Nilutamide has no biosimilar pathway.
- Licensing value is most likely to arise from regional distribution, API supply, contract manufacturing, or validated differentiated formulations.
- Excipient selection cannot mitigate nilutamide's intrinsic hepatic and pulmonary safety risks; formulation changes should preserve the established exposure profile.
FAQs About Nilutamide Excipient and Commercial Strategy
Can nilutamide be formulated without lactose?
Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or co-processed fillers can replace lactose, subject to dissolution, stability, and bioequivalence testing.
Is nilutamide suitable for an extended-release formulation?
The commercial rationale is limited because nilutamide is already administered once daily after the initial loading period. Modified release would require a clear pharmacokinetic or tolerability benefit.
Does nilutamide have biosimilar competition?
No. Nilutamide is a chemically synthesized small molecule. Competition proceeds through generic-drug or 505(b)(2) pathways rather than biosimilar approval.
What is the most attractive geographic market for a nilutamide generic?
Markets with limited access to newer androgen-receptor inhibitors and established demand for low-cost oncology medicines are more attractive than highly competitive U.S. channels.
Can a new nilutamide formulation receive patent protection?
Yes, if the formulation provides a novel and non-obvious technical result, such as materially improved dissolution, stability, dose uniformity, or clinically relevant pharmacokinetic performance.
References
-
U.S. Food and Drug Administration. (1996). Nilandron (nilutamide) prescribing information. Sanofi-Aventis U.S. LLC.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2025). FDA drug approval package for Nilandron (nilutamide). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/**
